OrgaNova TRiCBIO is a NAM-aligned organoid 2.0 platform built to help biotech, pharmaceutical, and research partners generate human-relevant translational evidence from discovery to preclinical decision-making.

Oncology drug development often fails when simplified models do not capture tumor-context biology, immune interactions, or microenvironment-driven response patterns. Our platform addresses this gap through patient-derived organoids, TME-preserving co-culture systems, PDOX bridge models, functional genomics, and multi-omics readouts designed to support model-informed decisions.

Our core focus is microenvironment-preserved patient-derived organoid modeling for translational oncology. We help R&D teams evaluate ex vivo drug response, immuno-oncology and CAR-T/TCR solid tumor barriers, ADC and targeted therapy activity, combination strategies, mechanism of action, biomarker hypotheses, and functional target validation.

Beyond individual assays, OrgaNova TRiCBIO builds integrated evidence packages for discovery, preclinical development, BD evaluation, and investor-facing diligence. Our work is designed to complement and refine preclinical evidence strategies, not to replace clinical or in vivo validation.

With China-based model-building capabilities and an expanding U.S. presence, we support cross-border research programs requiring patient-derived model context, customized assay development, and translational study design.

If your team is selecting models for oncology discovery, validating a target, evaluating an IO or cell therapy strategy, or building a BD-ready translational evidence package, contact us to discuss a fit-for-purpose study design.

TRiCBIO

Org chart

Teams

Offices

TRiCBIO

Org chart

Teams

Offices

Related companies